Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJ. Guigay, Franck Darloy, Cédrik Lafond et al.|The Lancet Oncology|2021Cited by 231
Unusual Adverse Event With Vandetanib in Metastatic Medullary Thyroid CancerSophie Duplomb, Christelle de la Fouchardière, Amandine Benoit et al.|Journal of Clinical Oncology|2011Cited by 7